Drug intelligence / Profile preview

AUR114

Development stage: Preclinical
Lead developer: Exelixis
Modality: Small Molecules
Administration: Intravitreal

Overview

AUR114 is a small molecule pan-KRAS inhibitor being developed by Aurigene Discovery Technologies. It is designed to target multiple oncogenic variants of the KRAS protein, which is a key driver in several difficult-to-treat malignancies. The drug is currently in the IND-enabling phase of development, with primary therapeutic focus on KRAS-mutated solid tumors, including lung cancer, pancreatic cancer, and colon cancer. By inhibiting a broad spectrum of KRAS mutations rather than a single specific allele, AUR114 aims to provide a more versatile treatment option for patients with KRAS-driven cancers.

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on AUR114.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AUR114.

Explore the full profile